William Blair analyst Sami Corwin has maintained their bullish stance on SLDB stock, giving a Buy rating on November 5.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sami Corwin has given his Buy rating due to a combination of factors that highlight Solid Biosciences’ strategic advancements and potential for growth. The recent licensing agreement with Andelyn Biosciences is a significant validation of Solid’s AAV-SLB101 technology, which is central to their lead program for treating Duchenne muscular dystrophy. This partnership not only enhances the credibility of Solid’s technology but also expands its reach by integrating with Andelyn’s proprietary manufacturing platform.
Furthermore, the collaboration is expected to accelerate data generation across various indications, thereby deepening the understanding of AAV-SLB101’s performance. This strategic move is seen as a positive step towards reinforcing Solid’s expertise and broadening its network of industry partnerships. Additionally, the anticipated interactions with the FDA regarding the SGT-003 program in the near future are likely to provide further clarity on the company’s regulatory pathway and potential market opportunities.
In another report released on November 5, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SLDB in relation to earlier this year.